Author: matias iglicki (Argentina)
Co-authors: David Pérez González, Dinah Zur, Prof Anat Loewenstein
Purpose
We aim to compare Long-lasting treatments for Neovascular Age Related Maculopathy . This Study cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.
Setting/Venue
Private Retina Office, University of Buenos Aires, Buenos Aires,Argentina Division of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Methods
Meta-analysis were we compare 700 patients treated with Brolucizumab, Faricimab, Abipicar, and Conbercept. for a 24 month follow up 24 Consecutive patients’ records were reviewed for drug stability and efficacy parameters, intra- and postoperative complications at 7 days, 1, 3, 6, 12, and 24 months after injection. Correlations between outcome measures and re treatment needed were analyzed.
Results
Although these new drugs have not shown superiority to the current standard of care in terms of vision gain, they do have the potential to improve real-world results by receiving less procedures per year i.e., improving patient’s compliance. Oour results reveled that these four drugs Brolucizumab, Faricimab, Abipicar, and Conbercept showed non statistical Differences in efficacy and safety profile ( p=0.001)
Conlusions
The long-lasting drugs discussed in this manuscript open the door for a better nAMD treatments. Others are expected to follow in the future. These long-lasting effect treatments should demonstrate better efficacy with longer effect and less frequent injec- tions, in order to ameliorate the current algorithm of treat- ment in nAMD. In consequence, these treatments might lead to achieve less frequent checkups and fewer side effects. While these aims have not been achieved yet, ongoing trials might offer us answers in the near future.
Financial Disclosure
'-Allergan – Consultant I -Bayer - Consultant -Novartis- Consultant -Regeneron- PI -Genentech-PI -TSK Laboratory Europe B.V.
Comments
-
